Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

Dyne Therapeutics, Inc. announced promising preclinical data for their therapeutic candidate, DYNE-302, which shows potential for functional improvement in facioscapulohumeral muscular dystrophy ...

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a ...

(Reuters) -Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would ...

Duchenne muscular dystrophy (DMD) has long been one of the most devastating genetic disorders to affect children. Marked by progressive muscle degeneration, early loss of mobility, and eventual ...

Visit a quote page and your recently viewed tickers will be displayed here.

Find the latest Dyne Therapeutics, Inc. (DYN) stock quote, history, news and other vital information to help you with your stock trading and investing.